Dynavax (DVAX) Tops Q4 EPS by 11c

Dynavax (NASDAQ: DVAX) reported Q4 EPS of $0.80, $0.11 better than the analyst estimate of $0.69. Revenue for the quarter came in at $195.1 million versus the consensus estimate of $208.87 million.

GUIDANCE:

2022 Financial GuidanceIn 2022, Dynavax anticipates:

• Full year CpG 1018 adjuvant net product revenues of at least $550 million, with associated gross margin of approximately 50%
• Selling, general and administrative expenses to be between approximately $120 - $140 million
• Research and development expenses to be between approximately $55 - $70 million
• Interest expense of approximately $7 million

For earnings history and earnings-related data on Dynavax (DVAX) click here.

You May Also Be Interested In

• Nurix Therapeutics, Inc. (NRIX) Reports Q3 EPS of $4.73
• Humana leads Managed Care winners in new CMS Star Ratings - Evercore
• SolarMax Technology (SMXT) Misses Q2 EPS by 98c